Literature DB >> 14669126

Initial experiences with the Impella device in patients with cardiogenic shock - Impella support for cardiogenic shock.

B Meyns1, J Dens, P Sergeant, P Herijgers, W Daenen, W Flameng.   

Abstract

BACKGROUND: We planned a study to assess the safety, feasibility, and efficacy of the Impella micro-axial blood pump in patients with cardiogenic shock.
METHODS: From January 2001 to September 2002 inclusive, 16 patients in cardiogenic shock (maximal inotropic support and with IABP in 11 cases) underwent left ventricle unloading with the Impella pump. 6 were placed via the femoral artery (patients in the coronary care unit) and 10 directly through the aorta (postcardiotomy heart failure). In three patients, the device was used in combination with ECMO. Mean age was 60 years (range 43 - 75), 11 were male.
RESULTS: A stable pump flow of 4.24 +/- 0.28 l/min was reached (3.3 +/- 1.9 l/min in patients with ECMO and Impella). Mean blood pressure before Impella) support was 57.4 +/- 13 mmHg, which increased to 74.9 +/- 13 mmHg after 6 hours and 80.6 +/- 17 mmHg (p = 0.003) after 24 hours. Cardiac output increased from 4.1 +/- 1.3 l/min to 5.5 +/- 1.3 (p = 0.003) and 5.9 +/-1.9 l/min (p = 0.01) at 6 and 24 hours. Mean pulmonary wedge pressure decreased from 29 +/- 10 mmHg to 17 +/- 5 mmHg and 18 +/- 7 mmHg at 6 (p = 0.04) and 24 hours. Blood lactate levels decreased significantly after 6 hours of support (from 2.7 +/- 1 to 1.3 +/- 0.5 mmol/l, p = 0.004). Device-related complications included three sensor failures (no clinical action), one pump displacement (replacement) and six incidences of haemolysis (peak free plasma haemoglobin > 100 mg/dl, no clinical action). Eleven patients (68 %) were weaned, six (37 %) survived.
CONCLUSIONS: Left ventricular unloading with the Impella pump via the transthoracic or femoral approach is feasible and safe. Support led to a decrease in pulmonary capillary wedge pressure, increase in cardiac output and mean blood pressure, and improved organ perfusion in patients with severe cardiogenic shock.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14669126     DOI: 10.1055/s-2003-45422

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  23 in total

1.  Percutaneous right ventricular support during catheter ablation of intra-atrial reentrant tachycardia in an adult with a mustard baffle--a novel use of the Impella device.

Authors:  Steven B Fishberger; Jeremy D Asnes; Nancy L Rollinson; Michael W Cleman
Journal:  J Interv Card Electrophysiol       Date:  2010-04-13       Impact factor: 1.900

Review 2.  Extra-corporeal membrane oxygenation for the post-cardiotomy patient.

Authors:  Priyadharshanan Ariyaratnam; Lindsay A McLean; Alexander R J Cale; Mahmoud Loubani
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

3.  Ventricular unloading with a miniature axial flow pump in combination with extracorporeal membrane oxygenation.

Authors:  Dirk Vlasselaers; Matthias Desmet; Lars Desmet; Bart Meyns; Joseph Dens
Journal:  Intensive Care Med       Date:  2006-01-24       Impact factor: 17.440

4.  Use of impella ventricular assist device in patients with severe coronary artery disease presenting with cardiac arrest.

Authors:  Venkata K Mukku; Qiangjun Cai; Syed Gilani; Ken Fujise; Alejandro Barbagelata
Journal:  Int J Angiol       Date:  2012-09

Review 5.  Percutaneous left ventricular assist devices during cardiogenic shock and high-risk percutaneous coronary interventions.

Authors:  Stéphane Cook; Stephan Windecker
Journal:  Curr Cardiol Rep       Date:  2009-09       Impact factor: 2.931

6.  Transapical miniaturized ventricular assist device: design and initial testing.

Authors:  Mark S Slaughter; Guruprasad A Giridharan; Dan Tamez; Jeff LaRose; Mike A Sobieski; Leslie Sherwood; Steven C Koenig
Journal:  J Thorac Cardiovasc Surg       Date:  2011-02-12       Impact factor: 5.209

7.  Percutaneous Hemodynamic Support (Impella) in Patients with Advanced Heart Failure and/or Cardiogenic Shock Not Eligible to PROTECT II Trial.

Authors:  Wei Liu; Venkata Kishore Mukku; Syed Gilani; Ken Fujise; Alejandro Barbagelata
Journal:  Int J Angiol       Date:  2013-12

8.  The Role of Percutaneous Haemodynamic Support in High-risk Percutaneous Coronary Intervention and Cardiogenic Shock.

Authors:  Dagmar M Ouweneel; Bimmer E Claessen; Krischan D Sjauw; José Ps Henriques
Journal:  Interv Cardiol       Date:  2015-03

Review 9.  Percutaneous ventricular assist devices for cardiogenic shock.

Authors:  Stéphane Cook; Stephan Windecker
Journal:  Curr Heart Fail Rep       Date:  2008-09

Review 10.  Contemporary device management of cardiogenic shock following acute myocardial infarction.

Authors:  Tariq Suleiman; Alexander Scott; David Tong; Vikram Khanna; Vijay Kunadian
Journal:  Heart Fail Rev       Date:  2021-03-03       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.